Journal Mobile Options
Table of Contents
Vol. 136, No. 1, 2005
Issue release date: January 2005
Section title: Original Paper
Int Arch Allergy Immunol 2005;136:45–52
(DOI:10.1159/000082584)

Severe Allergy to Sharon Fruit Caused by Birch Pollen

Bolhaar S.T.H.P.a · van Ree R.b · Ma Y.c · Bruijnzeel-Koomen C.A.F.M.a · Vieths S.d · Hoffmann-Sommergruber K.c · Knulst A.C.a · Zuidmeer L.b
aDepartment of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, bDepartment of Immunopathology, Sanquin, Amsterdam, The Netherlands; cDepartment of Pathophysiology, Medical University Vienna, Vienna, Austria; dDivision of Allergology, Paul Ehrlich Institute, Langen, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/3/2004
Accepted: 9/24/2004
Published online: 2/2/2005
Issue release date: January 2005

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Allergy to sharon fruit (persimmon) has been only rarely reported. Cross-reactivity with pollen (profilin and Bet v 6) appeared to be involved, but Bet v 1 has not been implicated previously. Objective: It is our aim to identify whether Bet v 1 sensitization is linked to sharon fruit allergy. Methods: Two patients with a reaction upon first exposure to sharon fruit were included in the study, as well as 7 patients with birch-pollen-related apple allergy. Sensitivity was assessed by skin prick testing (SPT), a radio-allergosorbent test (RAST) and immunoblotting. RAST analysis was performed for Bet v 1, Bet v 2 and Bet v 6. Cross-reactivity was evaluated by RAST and immunoblot inhibitions. Biological activity of IgE was measured by basophil histamine release. Sharon fruit allergy was evaluated by double-blind placebo-controlled food challenge (DBPCFC) or open challenge (OC). Results: Both sharon-fruit-allergic patients demonstrated positive reactions in the RAST (8.6 and 6.2 IU/ml, respectively) and SPT (wheal area 37 and 36 mm2). Sharon fruit allergy was confirmed by DBPCFC in 1 patient. The second patient refused a challenge because of the severe initial reaction. Sera from both patients were reactive to Bet v 1 and Bet v 6, which was cross-reactive with sharon fruit by inhibition assays. The patient with the severest reactions was reactive to profilin on immunoblotting. However, profilin did not induce significant histamine release, nor did Bet v 6. Bet v 1 induce approximately 60% histamine release. An OC with sharon fruit in 7 patients allergic to birch pollen and apple, who had not eaten sharon fruit previously, was positive in 6/7 cases. Conclusions: Birch-pollen-related allergy to sharon fruit is mediated by the known cross-reactive pollen allergens including Bet v 1 and may become more of a problem should sharon fruit consumption increase.

© 2005 S. Karger AG, Basel


  

Author Contacts

Correspondence to: S.T.H.P. Bolhaar, MD
Department of Dermatology/Allergology (G02.124)
University Medical Center, Utrecht, PO Box 85.500
NL–3508 GA Utrecht (The Netherlands)
Tel. +31 30 2507389, Fax +31 30 2505404, E-Mail S.Bolhaar@azu.nl

  

Article Information

Received: June 3, 2004
Accepted after revision: September 24, 2004
Published online: December 8, 2004
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 3, Number of References : 42

  

Publication Details

International Archives of Allergy and Immunology

Vol. 136, No. 1, Year 2005 (Cover Date: January 2005)

Journal Editor: R. Valenta, Vienna
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information: http://www.karger.com/iaa


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/3/2004
Accepted: 9/24/2004
Published online: 2/2/2005
Issue release date: January 2005

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.